AstraZeneca stock jumps as COPD drug trial win surprises market

Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its experimental chronic obstructive pulmonary disease (COPD) treatment, tozorakimab.

The UK-based pharmaceutical company said the drug candidate met its primary objective in two Phase 3 studies, OBERON and TITANIA, marking a significant milestone in its respiratory pipeline. 

The results showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo.

The trials met the primary endpoint across a broad patient population, including former smokers as well as the overall population comprising both former and current smokers. 

Patients across all blood eosinophil levels and stages of lung function severity were included in the studies.

Tozorakimab was generally well-tolerated, with a favorable safety profile, and was administered at a dose of 300 mg every four weeks alongside standard treatments.

AstraZeneca shares rose more than 4% on Friday, reflecting investor optimism following the announcement.

‘Positive surprise’ amid mixed results from rivals

The strong clinical data come at a time when competing drugmakers have struggled to deliver similar results. 

According to analysts at Bank of America, AstraZeneca’s success stands out in a challenging competitive landscape.

AstraZeneca's tozorakimab drug candidate hit the primary objective in two late-stage clinical studies for chronic obstructive pulmonary disease, a condition for which rival candidates from Roche and Sanofi recently fell short, Bank of America analysts say in a research note. 

In light of those prior failures, study results from the UK drugmaker come as a positive surprise, Bank of America says.

The treatment targets interleukin-33 (IL-33), a protein linked to inflammation in respiratory diseases. 

While AstraZeneca and Sanofi focused on former smokers, Roche targeted a broader patient population in its trials.

Earlier attempts by competitors, including itepekimab from Regeneron Pharmaceuticals and Sanofi, delivered mixed results, highlighting the difficulty of developing effective COPD therapies.

AstraZeneca said tozorakimab is the first IL-33-targeting drug to show such strong results in two Phase 3 COPD studies, underscoring its potential differentiation in the market.

Growth potential strengthens long-term outlook

The positive trial results are also seen as a key step toward AstraZeneca’s long-term financial goals. 

COPD remains a major global health challenge, affecting nearly 400 million people and ranking as the third leading cause of death worldwide.

Reuters has reported that AstraZeneca expects peak annual sales of tozorakimab to reach between $3 billion and $5 billion, indicating significant commercial potential.

“AstraZeneca's positive clinical-trial results for a drug candidate for chronic obstructive pulmonary disease bode well for its 2030 revenue target,” said AJ Bell's Russ Mould. 

“This breakthrough with experimental COPD treatment tozorakimab is an important building block as the company looks to achieve its 2030 target of $80 billion in annual revenue,” he added.

Beyond COPD, AstraZeneca continues to expand the drug’s potential applications. 

Additional Phase 3 trials, PROSPERO and MIRANDA, are ongoing, while tozorakimab is also being evaluated in a Phase 3 trial for severe viral lower respiratory tract disease and a Phase 2 trial in asthma.

The latest results reinforce AstraZeneca’s position in the respiratory therapeutics market and highlight the growing importance of innovative biologics in addressing complex chronic diseases.